Rafael Holdings Inc. said Sept. 14 it appointed Patrick Fabbio as its chief financial officer.
With more than 25 years of financial, operational and transactional leadership experience, Fabbio joins the Newark-based pharmaceutical holding company that is focused on developing novel cancer metabolism therapeutics through its Barer Institute and investment in Rafael Pharmaceuticals segments.
Prior to joining Rafael Holdings, Fabbio was chief financial officer of WindMIL Therapeutics Inc. Previously he served as the chief financial officer of Progenics Pharmaceuticals Inc., electroCore Medical LLC; vice president of finance at NPS Pharmaceuticals Inc.; vice president of finance, innovation and growth at Catalent Pharma Solutions Inc.; and chief financial officer at Ikano Therapeutics.
“Pat joins our growing executive management team as we work to build a high growth, fully integrated cancer metabolism therapeutics company focused on improving and extending the lives of cancer patients,” said Ameet Mallik, chief executive officer of Rafael Holdings.
Other prior financial positions Fabbio has held include roles at Sanofi, UniPath Diagnostics, BioMatrix and Coopers & Lybrand. Patrick is a board member of BeyondSpring Therapeutics Inc.
“I am excited to work with Ameet and the Rafael Holdings team to build a commercial-ready leading cancer metabolism therapeutics company with the potential to address a large range of cancer indications and improve the lives of patients with unmet medical need,” Fabbio said in a prepared statement.
